|
Mechanism-based peripheral blood biomarkers to evaluate anticancer effects of the plinabulin/docetaxel combination (plin/doc) vs. doc alone in second/third line EGFR wild-type (WT) NSCLC. |
|
|
Employment - Piedmont Cancer Institute |
Stock and Other Ownership Interests - OneOncology |
Consulting or Advisory Role - AstraZeneca; Janssen; Menarini; Seagen |
Speakers' Bureau - Sanofi; SOBI |
|
|
No Relationships to Disclose |
|
|
Employment - BeyondSpring Pharmaceuticals |
|
|
No Relationships to Disclose |
|
|
Employment - BeyondSpring Pharmaceuticals |
Leadership - BeyondSpring Pharmaceuticals |
Stock and Other Ownership Interests - BeyondSpring Pharmaceuticals |
Patents, Royalties, Other Intellectual Property - BeyondSpring Pharmaceuticals |
|
|
Employment - BeyondSpring Pharmaceuticals |
Leadership - BeyondSpring Pharmaceuticals |
Stock and Other Ownership Interests - BeyondSpring Pharmaceuticals |